Helen Torley Sells 20,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) CEO Helen Torley sold 20,000 shares of the stock in a transaction dated Friday, June 20th. The stock was sold at an average price of $52.96, for a total value of $1,059,200.00. Following the sale, the chief executive officer now owns 733,719 shares of the company's stock, valued at $38,857,758.24. This represents a 2.65% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Helen Torley also recently made the following trade(s):

• On Tuesday, June 24th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $53.73, for a total value of $1,074,600.00.

Halozyme Therapeutics Trading Up 2.1%

Shares of HALO stock traded up $1.10 on Tuesday, reaching $53.90. 1,961,181 shares of the company's stock were exchanged, compared to its average volume of 1,651,430. Halozyme Therapeutics, Inc. has a 52 week low of $42.01 and a 52 week high of $70.51. The company has a current ratio of 8.39, a quick ratio of 7.30 and a debt-to-equity ratio of 3.13. The stock has a market capitalization of $6.64 billion, a PE ratio of 12.45, a P/E/G ratio of 0.35 and a beta of 1.19. The company's fifty day simple moving average is $56.56 and its 200 day simple moving average is $56.38.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.98 by $0.13. The firm had revenue of $264.86 million during the quarter, compared to analyst estimates of $231.21 million. Halozyme Therapeutics had a return on equity of 136.91% and a net margin of 44.76%. Halozyme Therapeutics's quarterly revenue was up 35.2% compared to the same quarter last year. During the same period last year, the company earned $0.79 EPS. As a group, analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Institutional Investors Weigh In On Halozyme Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Venturi Wealth Management LLC bought a new stake in Halozyme Therapeutics during the 4th quarter valued at $69,000. D. E. Shaw & Co. Inc. raised its position in Halozyme Therapeutics by 171.2% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 831,414 shares of the biopharmaceutical company's stock valued at $39,750,000 after purchasing an additional 524,802 shares in the last quarter. Fifth Third Bancorp increased its holdings in shares of Halozyme Therapeutics by 29.4% in the 1st quarter. Fifth Third Bancorp now owns 10,017 shares of the biopharmaceutical company's stock valued at $639,000 after acquiring an additional 2,276 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in shares of Halozyme Therapeutics by 0.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,783,177 shares of the biopharmaceutical company's stock valued at $85,254,000 after acquiring an additional 9,780 shares during the period. Finally, Farther Finance Advisors LLC increased its holdings in shares of Halozyme Therapeutics by 620.5% in the 1st quarter. Farther Finance Advisors LLC now owns 5,505 shares of the biopharmaceutical company's stock valued at $341,000 after acquiring an additional 4,741 shares during the period. 97.79% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have weighed in on HALO. Leerink Partners cut Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price target for the company. in a report on Tuesday, May 13th. JPMorgan Chase & Co. raised their price target on Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a report on Monday, April 21st. Wells Fargo & Company raised their price target on Halozyme Therapeutics from $60.00 to $65.00 and gave the company an "equal weight" rating in a report on Wednesday, May 7th. Morgan Stanley cut Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and cut their price target for the company from $73.00 to $62.00 in a report on Wednesday, May 14th. Finally, HC Wainwright restated a "buy" rating and set a $72.00 price target on shares of Halozyme Therapeutics in a report on Thursday, May 29th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $61.90.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.